atopic dermatitis

IPO initial public offering
Biotech

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Attovia has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
Nick Paul Taylor Jul 15, 2026 4:09am
IPO

Talawar heads to Nasdaq via SPAC deal to fund eczema bispecific

Jun 29, 2026 7:00am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

Jun 22, 2026 7:59am
sailing boat water yacht ocean wind

Windward breezes toward phase 3 with $165M for TSLP ambitions

May 4, 2026 10:31am
Sanofi headquarters Sanofi

Sanofi bispecific sees respiratory ph. 2 wins, eczema fail

Apr 7, 2026 4:10am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am